Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.41 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21046142 | 1.00 | ELANE (0.41) | ELANEPLCG1HTTHTR2AFAP | |
| SCHEMBL21046139 | 1.00 | ELANE (0.41) | ELANEPLCG1HTTHTR2AFAP | |
| SCHEMBL21046140 | 1.00 | ELANE (0.41) | ELANEPLCG1HTTHTR2AFAP | |
| SCHEMBL10757693 | 0.88 | ELANE (0.42) | ELANEPLCG1HTTHTR2AFAP | |
| SCHEMBL10757697 | 0.88 | ELANE (0.42) | ELANEPLCG1HTTHTR2AFAP | |
| SCHEMBL10757699 | 0.88 | ELANE (0.42) | ELANEPLCG1HTTHTR2AFAP | |
| SCHEMBL10759791 | 0.87 | ELANE (0.42) | ELANEPLCG1HTTHTR2AFAP | |
| SCHEMBL10759800 | 0.87 | ELANE (0.42) | ELANEPLCG1HTTHTR2AFAP | |
| SCHEMBL10759797 | 0.87 | ELANE (0.42) | ELANEPLCG1HTTHTR2AFAP | |
| SCHEMBL10760791 | 0.85 | ELANE (0.39) | ELANEPLCG1HTTHTR2AFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695322-B2 | Inhibitors of bacterial growth | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190167637-A1 | NOVEL INHIBITORS OF BACTERIAL GROWTH | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167637-A1 | NOVEL INHIBITORS OF BACTERIAL GROWTH | DPEP1, PEPD, ANPEP | ELANE 164/4885PLCG1 2397/4885HTT 4646/4885 |
| US-10695322-B2 | Inhibitors of bacterial growth | DPEP1, PEPD, ANPEP | ELANE 180/4885PLCG1 2496/4885HTT 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.